236 related articles for article (PubMed ID: 15467659)
21. Could prophylactic monoclonal antibody improve kidney graft survival?
Pourmand G; Saraji A; Salem S; Mehrsai A; Nikoobakht MR; Taherimahmoudi M; Rezaeidanesh M; Asadpour A
Transplant Proc; 2009 Sep; 41(7):2794-6. PubMed ID: 19765437
[TBL] [Abstract][Full Text] [Related]
22. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial.
Margreiter R; Klempnauer J; Neuhaus P; Muehlbacher F; Boesmueller C; Calne RY
Am J Transplant; 2008 Jul; 8(7):1480-5. PubMed ID: 18510632
[TBL] [Abstract][Full Text] [Related]
23. Alemtuzumab induction in deceased donor kidney transplantation.
Huang E; Cho YW; Hayashi R; Bunnapradist S
Transplantation; 2007 Oct; 84(7):821-8. PubMed ID: 17984833
[TBL] [Abstract][Full Text] [Related]
24. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation.
Barth RN; Janus CA; Lillesand CA; Radke NA; Pirsch JD; Becker BN; Fernandez LA; Thomas Chin L; Becker YT; Odorico JS; D'Alessandro AM; Sollinger HW; Knechtle SJ
Transpl Int; 2006 Nov; 19(11):885-92. PubMed ID: 17018123
[TBL] [Abstract][Full Text] [Related]
25. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
Trzonkowski P; Zilvetti M; Friend P; Wood KJ
Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
[TBL] [Abstract][Full Text] [Related]
26. Reversal of acute cellular rejection after renal transplantation with Campath-1H.
Basu A; Ramkumar M; Tan HP; Khan A; McCauley J; Marcos A; Fung JJ; Starzl TE; Shapiro R
Transplant Proc; 2005 Mar; 37(2):923-6. PubMed ID: 15848576
[TBL] [Abstract][Full Text] [Related]
27. Campath-1H use in pediatric renal transplantation.
Bartosh SM; Knechtle SJ; Sollinger HW
Am J Transplant; 2005 Jun; 5(6):1569-73. PubMed ID: 15888071
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
Ciancio G; Burke GW; Suzart K; Vaidya A; Roth D; Kupin W; Mattiazzi A; Rosen A; Esquenazi V; Miller J
Transplant Proc; 2003 Mar; 35(2):873-4. PubMed ID: 12644172
[No Abstract] [Full Text] [Related]
29. Polyclonal versus monoclonal induction therapy in a calcineurin inhibitor-free immunosuppressive therapy in renal transplantation: a comparison of efficacy and costs.
Sánchez-Escuredo A; Alsina A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofan F; Fernandez E; Campistol JM; Oppenheimer F
Transplant Proc; 2015; 47(1):45-9. PubMed ID: 25645767
[TBL] [Abstract][Full Text] [Related]
30. C4d positivity is often associated with acute cellular rejection in renal transplant biopsies following Campath-1H (Alemtuzumab) induction.
Zhang PL; Malek SK; Blasick TM; Pennington JR; Masker KK; Lun M; Potdar S
Ann Clin Lab Sci; 2007; 37(2):121-6. PubMed ID: 17522366
[TBL] [Abstract][Full Text] [Related]
31. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
Morales J; Bono MR; Fierro A; Iñiguez R; Zehnder C; Rosemblatt M; Calabran L; Herzog C; Benavente D; Aguiló J; Pefaur J; Alba A; Ferrario M; Simon W; Contreras L; Buckel E
Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of late immunologic parameters among renal transplant recipients induced with Campath-1H.
Alba A; Morales J; Fierro A; Zehnder C; Cao C; Orozco R; Herzog C; Calabrán L; Contreras L; Buckel E
Transplant Proc; 2010; 42(1):253-6. PubMed ID: 20172322
[TBL] [Abstract][Full Text] [Related]
33. Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients.
Csapo Z; Benavides-Viveros C; Podder H; Pollard V; Kahan BD
Transplant Proc; 2005 Jun; 37(5):2032-6. PubMed ID: 15964331
[TBL] [Abstract][Full Text] [Related]
34. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).
Kirk AD; Hale DA; Mannon RB; Kleiner DE; Hoffmann SC; Kampen RL; Cendales LK; Tadaki DK; Harlan DM; Swanson SJ
Transplantation; 2003 Jul; 76(1):120-9. PubMed ID: 12865797
[TBL] [Abstract][Full Text] [Related]
35. Campath induction for kidney transplantation: report of 297 cases.
Ortiz J; Palma-Vargas J; Wright F; Bingaman A; Agha I; Rosenblatt S; Foster P
Transplantation; 2008 Jun; 85(11):1550-6. PubMed ID: 18551058
[TBL] [Abstract][Full Text] [Related]
36. Cyclosporine-sparing effect of basiliximab in renal transplant recipients with mycophenolate mofetil.
Tojimbara T; Sato S; Koyama I; Nanmoku K; Sekijima M; Tonsyo M; Kai K; Kato Y; Urashima Y; Nakajima I; Fuchinoue S; Teraoka S
Transplant Proc; 2005 Mar; 37(2):895-8. PubMed ID: 15848568
[TBL] [Abstract][Full Text] [Related]
37. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
38. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
Sarwal MM; Vidhun JR; Alexander SR; Satterwhite T; Millan M; Salvatierra O
Transplantation; 2003 Nov; 76(9):1331-9. PubMed ID: 14627912
[TBL] [Abstract][Full Text] [Related]
39. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.
Kovac D; Kotnik V; Kandus A
Transplant Proc; 2005 Dec; 37(10):4230-4. PubMed ID: 16387086
[TBL] [Abstract][Full Text] [Related]
40. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]